ZoomInfo (GTM)

NASDAQCommunication ServicesSoftware - ApplicationSnapshot 2026-10-23

$4.35+0.93%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge ZoomInfo’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

0.0%

+10% or more+5%0%−5%−10% or less

1.13 → 1.13 EPS · FY ending Dec 31, 2027 · 13 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 13 to 13; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q3
Revenue	$298M–$301MGAAP	—
EPS	$0.28–$0.29non-GAAP	—
Operating income	$113M–$115Mnon-GAAP	—
FY 2026 · Q4
Revenue	—	291.78M
EPS	—	0.286
FY 2026 · Annual
Revenue	—	1.21B
EPS	—	1.126
FY 2027 · Annual
Revenue	—	1.18B
EPS	—	1.132

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Amend credit agreement to improve financial flexibility	A supporting condition in ZoomInfo's published investment case. The stated target is Successful amendment of credit agreement.	Intact	Failure to amend credit agreement by end of 2026	Amendment executed May 8, 2026 vs 2026 deadline May 2026 filing confirms entry into Credit Agreement Amendment with Morgan Stanley, satisfying the flexibility goal. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Generate free cash flow near $450 million in FY 2026	A supporting condition in ZoomInfo's published investment case. The stated target is ~$450 million.	Improving	Free cash flow falls below $400 million in FY26	Free cash flow: $160.3M FY2026-Q2; GAAP. Published target: ~$450 million. Target period is not explicitly aligned with this observation. Source published Aug 5, 2026160,300,000 USD · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Increase operating income to at least $57.9 million in Q1 2026	Operating income rose to $57.9 million in Q1 2026.	Intact	Operating income falls below $50 million in Q1 2026	Operating income: $-622M FY2026-Q2; GAAP. Published target: >= $57.9 million. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 5, 2026-622,000,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 95776e32-db11-48d0-b938-750afa892e62. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. The 2026 Restructuring Program aims to reduce operating costs and improve leverage with estimated pre-tax charges of $45 million to $60 million and a workforce reduction of about 600 employees. Management has reiterated this program since 2026-Q1 and the financials show operating expenses remain elevated but with focus on cost discipline, indicating ongoing execution. Delivery assessment Oct 24, 2026
Achieve FY 2026 revenue near $1.257 billion	A primary condition in ZoomInfo's published investment case. The stated target is ~$1.257 billion.	Broken	Revenue falls below $1.2 billion in FY26	Revenue: $310.4M FY2026-Q2; GAAP. Published target: ~$1.257 billion. Target period is not explicitly aligned with this observation. Source published Aug 5, 2026310,400,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 95776e32-db11-48d0-b938-750afa892e62. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. FY 2026 GAAP revenue guidance has been provided in a range narrowing from $1.247-$1.267 billion in 2026-Q1 to $1.185-$1.217 billion in 2026-Q2 and 2026-Q3 guidance at $298-$301 million quarterly. Actual revenue grew modestly from $305.7 million in 2025-Q1 to $310.4 million in 2026-Q2, indicating steady progress toward the annual revenue target. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$1.13

$1.11 → $1.13 · observed estimates

FY2027 revenue$1.18B

$1.17B → $1.18B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$1.11	$1,171,348,141	13 / 16
2026-07-25	$1.11	$1,170,511,440	22 / 21
2026-07-26	$1.11	$1,171,348,141	13 / 16
2026-07-27	$1.11	$1,171,348,141	13 / 16
2026-07-28	$1.11	$1,171,348,141	13 / 16
2026-07-29	$1.11	$1,170,511,440	22 / 21
2026-07-30	$1.11	$1,170,511,440	22 / 21
2026-07-31	$1.11	$1,170,511,440	22 / 21
2026-08-01	$1.11	$1,171,350,541	13 / 16
2026-08-02	$1.11	$1,171,350,541	13 / 16
2026-08-03	$1.11	$1,170,511,440	22 / 21
2026-08-04	$1.11	$1,170,511,440	22 / 21
2026-08-05	$1.11	$1,170,511,440	22 / 21
2026-08-06	$1.11	$1,170,511,440	22 / 21
2026-08-07	$1.12	$1,182,725,144	13 / 16
2026-08-08	$1.13	$1,184,153,640	21 / 20
2026-08-09	$1.13	$1,184,153,640	21 / 20
2026-08-10	$1.13	$1,184,153,640	21 / 20
2026-08-12	$1.13	$1,183,209,540	21 / 20
2026-08-13	$1.12	$1,182,725,144	13 / 16
2026-08-14	$1.12	$1,182,725,144	13 / 16
2026-08-15	$1.12	$1,182,725,144	13 / 16
2026-08-16	$1.12	$1,182,725,144	13 / 16
2026-08-17	$1.12	$1,182,725,144	13 / 16
2026-08-18	$1.12	$1,182,725,144	13 / 16
2026-08-19	$1.12	$1,182,725,144	13 / 16
2026-08-20	$1.13	$1,183,126,038	13 / 16
2026-08-21	$1.13	$1,183,126,038	13 / 16
2026-08-22	$1.13	$1,183,126,038	13 / 16
2026-08-23	$1.13	$1,183,126,038	13 / 16
2026-08-24	$1.13	$1,183,126,038	13 / 16
2026-08-25	$1.13	$1,183,126,038	13 / 16
2026-08-26	$1.13	$1,183,126,038	13 / 16
2026-08-27	$1.13	$1,183,126,038	13 / 16
2026-08-28	$1.13	$1,183,126,038	13 / 16
2026-08-29	$1.13	$1,183,126,038	13 / 16
2026-08-30	$1.13	$1,183,126,038	13 / 16
2026-08-31	$1.13	$1,183,126,038	13 / 16
2026-09-01	$1.13	$1,183,126,038	13 / 16
2026-09-02	$1.13	$1,183,126,038	13 / 16
2026-09-03	$1.13	$1,183,126,038	13 / 16
2026-09-04	$1.13	$1,183,126,038	13 / 16
2026-09-05	$1.13	$1,183,126,038	13 / 16
2026-09-06	$1.13	$1,183,126,038	13 / 16
2026-09-07	$1.13	$1,183,126,038	13 / 16
2026-09-08	$1.13	$1,183,126,038	13 / 16
2026-09-09	$1.13	$1,183,126,038	13 / 16
2026-09-10	$1.13	$1,183,126,038	13 / 16
2026-09-11	$1.13	$1,183,126,038	13 / 16
2026-09-12	$1.13	$1,183,126,038	13 / 16
2026-09-13	$1.13	$1,183,126,038	13 / 16
2026-09-14	$1.13	$1,183,126,038	13 / 16
2026-09-15	$1.13	$1,183,126,038	13 / 16
2026-09-16	$1.13	$1,183,126,038	13 / 16
2026-09-17	$1.13	$1,183,126,038	13 / 16
2026-09-18	$1.13	$1,183,126,038	13 / 16
2026-09-19	$1.13	$1,183,126,038	13 / 16
2026-09-20	$1.13	$1,183,126,038	13 / 16
2026-09-21	$1.13	$1,183,126,038	13 / 16
2026-09-22	$1.13	$1,183,126,038	13 / 16
2026-09-23	$1.13	$1,183,126,038	13 / 16
2026-09-24	$1.13	$1,183,126,038	13 / 16
2026-09-25	$1.13	$1,183,126,038	13 / 16
2026-09-26	$1.13	$1,183,126,038	13 / 16
2026-09-27	$1.13	$1,183,126,038	13 / 16
2026-09-28	$1.13	$1,183,126,038	13 / 16
2026-09-29	$1.13	$1,183,126,038	13 / 16
2026-09-30	$1.13	$1,183,126,038	13 / 16
2026-10-01	$1.13	$1,183,126,038	13 / 16
2026-10-02	$1.13	$1,183,126,038	13 / 16
2026-10-03	$1.13	$1,183,126,038	13 / 16
2026-10-04	$1.13	$1,183,126,038	13 / 16
2026-10-05	$1.13	$1,183,126,038	13 / 16
2026-10-06	$1.13	$1,183,126,038	13 / 16
2026-10-07	$1.13	$1,183,126,038	13 / 16
2026-10-08	$1.13	$1,183,126,038	13 / 16
2026-10-09	$1.13	$1,183,126,038	13 / 16
2026-10-10	$1.13	$1,183,126,038	13 / 16
2026-10-11	$1.13	$1,183,126,038	13 / 16
2026-10-12	$1.13	$1,183,126,038	13 / 16
2026-10-13	$1.13	$1,183,126,038	13 / 16
2026-10-14	$1.13	$1,183,126,038	13 / 16
2026-10-15	$1.13	$1,183,126,038	13 / 16
2026-10-16	$1.13	$1,183,126,038	13 / 16
2026-10-17	$1.13	$1,183,126,038	13 / 16
2026-10-18	$1.13	$1,183,128,138	13 / 16
2026-10-19	$1.13	$1,183,128,138	13 / 16
2026-10-20	$1.13	$1,183,128,138	13 / 16
2026-10-21	$1.13	$1,183,128,138	13 / 16
2026-10-22	$1.13	$1,183,128,138	13 / 16
2026-10-23	$1.13	$1,183,128,138	13 / 16
2026-10-24	$1.13	$1,183,128,138	13 / 16

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	6	13	7
2026-06-01	2	13	7
2026-07-01	2	13	7
2026-08-01	2	13	7
2026-09-01	2	13	7
2026-10-01	2	13	7

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 2 Buy / Strong Buy · 13 Hold · 7 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Generate free cash flow near $450 million in FY 2026Free cash flow: $160.3M
Increase operating income to at least $57.9 million in Q1 2026Operating income: $-622M
Achieve FY 2026 revenue near $1.257 billionPublished status: Broken

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.1%Typical daily move · historical

Downside history

-77.9%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

ZoomInfo outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

GTM is a restructuring and execution-dependent business, rather than a proven durable compounder, with a loss-making profile. The multi-year view is on watch: revenue guidance is on track, while recent financial performance trails its industry cohort and confidence has eased to medium.

What's priced into ZoomInfo

GTM is described as cheap versus peers, but the valuation model has low confidence and shows a 27% premium versus peers, so the relative valuation evidence is mixed. The expectations gap is negative, while the priced-in assessment is tagged justified with low fragility; the evidence does not clearly specify what operating expectations the market assumes.

What the fundamentals likely do

Near term, revenue has grown modestly and quarterly guidance is provided, while operating costs remain elevated as management works through a restructuring that includes workforce reductions and one-time charges. Share repurchases and debt reduction are ongoing, but recent financial performance is weak, sector conditions are a headwind, and a litigation filing adds uncertainty.

What ZoomInfo hinges on

Over the next few quarters, the thesis depends on management executing the restructuring and meeting revenue guidance without a guidance cut. A cut would be a meaningful negative; rate cuts or stronger results and guidance from sector peers could support the business backdrop, though these are uncertain.